Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours
Trial summary:
A randomised, multi-centre, phase II/III trial to determine whether in patients with mutation positive advanced NSCLC the use of SBRT to ≤ 5 sites of oligoprogressive disease (OPD) with continuation of tyrosine kinase inhibitor (TKI) improves progression-free survival (PFS) compared with continuation of TKI alone
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | | ||
| Planning Benchmark Case | | ||
| Dummy Run | |||
| During Accrual | Individual Case Review | | Prospective for all patient |
| Data collection | | All patients | |
| Dosimetry | | ||
| QA Streamlining | | CtE, SEP, TRAP, SARON SABR QA programmes for pre-accrual and audit |
RTTQA contact: Haltqa.enh-tr@nhs.net
Chief investigator: Dr Fiona McDonald, Royal Marsden NHS Foundation Trust
Sponsor: Royal Marsden NHS Foundation Trust
CTU: halt-icrctsu@icr.ac.uk
Funder: CRUK